EUVIMEDEUVIMED entdecken
Open Access

Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy

Saad N Mohammad, Yeon Su Choi, Jee Young Chung, Edward Cedrone, Barry W Neun, Marina A Dobrovolskaia, Xiaojing Yang, Wei Guo, Yap Ching Chew, Juwan Kim, Seunggul Baek, Ik Soo Kim und 2 weitere

Journal of Controlled Release · 2023

DOI: 10.1016/j.jconrel.2022.12.048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Saad N Mohammad und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697, United States. Hauptthemen laut MEDLINE: Doxorubicin, Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-targeted therapy by a chemotherapeutic agent formulated in a nanoscale platform has been challenged by complex and inefficient manufacturing, low drug loading, difficult characterization, and marginally improved therapeutic efficacy. This study investigated facile-to-produce nanocomplexes of doxorubicin (DOX), a widely used cancer drug, and clinically approved DNA fragments that are extracted from a natural source. DOX was found to self-assemble DNA fragments into relatively monodispersed nanocomplexes with a diameter of ∼70 nm at 14.3% (w/w) drug loading by simple and scalable mixing. The resulting DOX/DNA nanocomplexes showed sustained DOX release, unlike overly stable Doxil®, cellular uptake via multiple endocytosis pathways, and high hematological and immunological compatibility. DOX/DNA nanocomplexes eradicated EL4 T lymphoma cells in a time-dependent manner, eventually surpassing free DOX. Extended circulation of DOX/DNA nanocomplexes, while avoiding off-target accumulation in the lung and being cleared from the liver, resulted in rapid accumulation in tumor and lowered cardio toxicity. Finally, tumor growth of EL4-challenged C57BL/6 mice (syngeneic model) and OPM2-challenged NSG mice (human xenograft model) were efficiently inhibited by DOX/DNA nanocomplexes with enhanced overall survival, in comparison with free DOX and Doxil®, especially upon repeated administrations. DOX/DNA nanocomplexes are a promising chemotherapeutics delivery platform for their ease of manufacturing, high biocompatibility, desired drug release and accumulation, efficient tumor eradication with improved safety, and further engineering versatility for extended therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinNeoplasmsHumansMiceAnimalsCell Line, TumorMice, Inbred C57BLDrug Delivery SystemsDNA AdductsPolyethylene Glycols

Stichwörter der Autor:innen

Cancer therapyDNA fragmentsDoxorubicinEfficacy and safetyNanocomplexes

Substanzen

DoxorubicinDNA Adductsliposomal doxorubicinPolyethylene Glycolsdoxorubicin-DNA

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697, United States.
  • Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, United States.
  • Zymo Research Corporation, Irvine, CA 92604, United States.
  • Pharma Research, Co, Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea.
  • Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, United States.
  • Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697, United States; Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, United States; Department o…

Förderung

  • NCI NIH HHS

Zitieren

APA

Mohammad, S. N., Choi, Y. S., Chung, J. Y., Cedrone, E., Neun, B. W., Dobrovolskaia, M. A., Yang, X., Guo, W., Chew, Y. C., Kim, J., Baek, S., Kim, I. S., Fruman, D. A., & Kwon, Y. J. (2023). Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2022.12.048

Vancouver

Mohammad SN, Choi YS, Chung JY, Cedrone E, Neun BW, Dobrovolskaia MA, et al. Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2022.12.048

BibTeX
@article{Mohammad2023,
  author = {Mohammad, Saad N and Choi, Yeon Su and Chung, Jee Young and Cedrone, Edward and Neun, Barry W and Dobrovolskaia, Marina A and Yang, Xiaojing and Guo, Wei and Chew, Yap Ching and Kim, Juwan and Baek, Seunggul and Kim, Ik Soo and Fruman, David A and Kwon, Young Jik},
  title = {Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy},
  journal = {Journal of Controlled Release},
  year = {2023},
  doi = {10.1016/j.jconrel.2022.12.048}
}
Kostenlos starten →